PT3972604T - Inibidor da tirosina quinase de bruton para utilização no tratamento da urticária crónica espontânea - Google Patents

Inibidor da tirosina quinase de bruton para utilização no tratamento da urticária crónica espontânea

Info

Publication number
PT3972604T
PT3972604T PT207292046T PT20729204T PT3972604T PT 3972604 T PT3972604 T PT 3972604T PT 207292046 T PT207292046 T PT 207292046T PT 20729204 T PT20729204 T PT 20729204T PT 3972604 T PT3972604 T PT 3972604T
Authority
PT
Portugal
Prior art keywords
bruton
methods
tyrosine kinase
kinase inhibitor
treating chronic
Prior art date
Application number
PT207292046T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT3972604T publication Critical patent/PT3972604T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT207292046T 2019-05-23 2020-05-20 Inibidor da tirosina quinase de bruton para utilização no tratamento da urticária crónica espontânea PT3972604T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962851996P 2019-05-23 2019-05-23

Publications (1)

Publication Number Publication Date
PT3972604T true PT3972604T (pt) 2025-08-26

Family

ID=70918751

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207292046T PT3972604T (pt) 2019-05-23 2020-05-20 Inibidor da tirosina quinase de bruton para utilização no tratamento da urticária crónica espontânea

Country Status (22)

Country Link
US (2) US12419889B2 (https=)
EP (2) EP4599894A3 (https=)
JP (2) JP7568651B2 (https=)
KR (1) KR20220012281A (https=)
CN (1) CN113795255A (https=)
AU (2) AU2020280272B2 (https=)
BR (1) BR112021022602A2 (https=)
CA (1) CA3138081A1 (https=)
CL (1) CL2021003032A1 (https=)
DK (1) DK3972604T3 (https=)
ES (1) ES3039974T3 (https=)
FI (1) FI3972604T3 (https=)
HR (1) HRP20251001T1 (https=)
IL (1) IL286983B2 (https=)
LT (1) LT3972604T (https=)
MX (2) MX2021013942A (https=)
PL (1) PL3972604T3 (https=)
PT (1) PT3972604T (https=)
RS (1) RS67141B1 (https=)
SI (1) SI3972604T1 (https=)
TW (2) TW202537625A (https=)
WO (1) WO2020234782A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67141B1 (sr) 2019-05-23 2025-09-30 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije
JP7564347B2 (ja) 2021-09-03 2024-10-08 ノバルティス アーゲー 多発性硬化症を治療するためのlou064
US20250032488A1 (en) 2021-12-14 2025-01-30 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用lou064治療化膿性汗腺炎之方法
KR102834740B1 (ko) * 2023-04-10 2025-07-17 아주대학교산학협력단 Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물
WO2024235163A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 Btk抑制剂的用途和单剂量药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2705719C (en) 2007-09-14 2016-10-11 Janssen Pharmaceutica N.V. Thieno-and furo-pyrimidine modulators of the histamine h4 receptor
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3092250A4 (en) 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2016079669A1 (en) * 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
RS67141B1 (sr) 2019-05-23 2025-09-30 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije

Also Published As

Publication number Publication date
TWI868139B (zh) 2025-01-01
SI3972604T1 (sl) 2025-09-30
US20220184074A1 (en) 2022-06-16
RS67141B1 (sr) 2025-09-30
KR20220012281A (ko) 2022-02-03
MX2021013942A (es) 2022-01-04
EP3972604B1 (en) 2025-06-04
CN113795255A (zh) 2021-12-14
EP4599894A2 (en) 2025-08-13
TW202110450A (zh) 2021-03-16
AU2025252618A1 (en) 2025-11-06
AU2020280272A1 (en) 2021-11-18
EP3972604A1 (en) 2022-03-30
JP2024178168A (ja) 2024-12-24
AU2020280272B2 (en) 2025-07-24
EP4599894A3 (en) 2025-11-12
DK3972604T3 (da) 2025-09-15
BR112021022602A2 (pt) 2022-01-04
CA3138081A1 (en) 2020-11-26
MX2024014626A (es) 2025-01-09
CL2021003032A1 (es) 2022-09-09
IL286983B2 (en) 2026-01-01
JP2022533981A (ja) 2022-07-27
LT3972604T (lt) 2025-09-10
WO2020234782A1 (en) 2020-11-26
JP7568651B2 (ja) 2024-10-16
IL286983B1 (en) 2025-09-01
HRP20251001T1 (hr) 2025-10-24
IL286983A (en) 2021-12-01
ES3039974T3 (en) 2025-10-28
FI3972604T3 (fi) 2025-09-01
PL3972604T3 (pl) 2025-09-22
US12419889B2 (en) 2025-09-23
US20250375446A1 (en) 2025-12-11
TW202537625A (zh) 2025-10-01

Similar Documents

Publication Publication Date Title
PT3972604T (pt) Inibidor da tirosina quinase de bruton para utilização no tratamento da urticária crónica espontânea
PT3972603T (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
IL274716A (en) Synthesis of a proton tyrosine kinase inhibitor
IL255831A (en) Inhibitors of bruton's tyrosine kinase
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
IL283599A (en) Tyrosine kinase inhibitors, preparations and methods
IL259862B (en) Inhibitors of proton tyrosine kinase and methods of using them
EP3273961A4 (en) Solvated forms of a bruton's tyrosine kinase inhibitor
IL286727A (en) fgfr tyrosine kinase inhibitors for the treatment of urinary tract carcinoma
IL272350A (en) Therapeutic combination of a third-generation EGFR tyrosine kinase inhibitor and a RAF inhibitor
ZA202102274B (en) Use of casein kinase 1 inhibitors for treating vascular diseases
IL285136A (en) bay1895344 kinase atr inhibitor for use in the treatment of hyperproliferative disease
IL277474A (en) Methods for the treatment of chronic spontaneous urticaria using ligizumab
IL284916A (en) Cyclic molecules as Bruton's tyrosine kinase inhibitors
ZA202202617B (en) Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor
EP3999064A4 (en) Inhibitors of tyrosine kinase
SG10201909596RA (en) Synthesis of Tyrosine Kinase Inhibitors
EP4069689A4 (en) SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON TYROSINKINASE INHIBITORS
ZA202103858B (en) Tyrosine kinase inhibitors, compositions and methods there of
HK40036558A (en) Methods of treating chronic spontaneous urticaria using ligelizumab
HK40072430A (en) Dosing of a bruton's tyrosine kinase inhibitor
HK40075155A (en) Inhibitors of tyrosine kinase